(MedPage Today) — SAN FRANCISCO — A once-yearly intramuscular lenacapavir (Sunlenca) injection was safe and well-tolerated and had higher median levels of plasma concentrations compared with twice-yearly subcutaneous lenacapavir for HIV pre…
Source link : https://www.medpagetoday.com/meetingcoverage/croi/114653
Author :
Publish date : 2025-03-14 14:37:00
Copyright for syndicated content belongs to the linked Source.
